• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

OncoPep

edit

OncoPep, Inc. was founded in 2010 to commercialize a novel approach to developing targeted immunotherapeutics against cancer. The Company’s proprietary core technology was developed in the laboratory of Dr. Kenneth Anderson, M.D., a world leader in cancer treatment, at the Dana Farber Cancer Institute. The technology, which OncoPep has exclusively licensed from Dana Farber, employs a unique combination of proprietary peptides to form a therapeutic cancer vaccine. Vaccines developed from this technology are designed to stimulate the patient’s immune system to attack his or her cancer through an optimized combination of disease-specific peptides and adjuvants (substances that stimulate the immune system). Strong scientific rationale exists for this multi-peptide approach.

Milestones

edit

• 
  OncoPep added Doris Peterkin as CEO.
  Posted 2/13/12 at 8:12pm
• 
  OncoPep received $2.5M in Venture Round funding. (4/26/12)
  Posted 4/26/12 at 6:12pm via masshightech.com
• 
  OncoPep received $500k in Series A funding. (2/13/12)
  Posted 2/13/12 at 8:14pm via masshightech.com
• 
  OncoPep received $4.5M in Series A funding. (4/15/11)
  Posted 4/15/11 at 10:32pm via masshightech.com

Videos

Screenshots

edit

Above: Home page
Uploaded: 2/14/12

Sources

1. OncoPep launches with eye on $4.5M funding (masshightech.com) [edit]
2. OncoPep licenses cancer vaccine, moves to add $500K to Series A (masshightech.com) [edit]
3. OncoPep raises $2.5M (masshightech.com) [edit]